Breast Cancer CDK4/6 Inhibitors in Patients with metastatic HR+/HER2-Breast Cancer

被引：0
|
作者：
Schmale, Ine
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷 / 1-2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
    Cogliati, Viola
    Capici, Serena
    Pepe, Francesca Fulvia
    di Mauro, Pierluigi
    Riva, Francesca
    Cicchiello, Federica
    Maggioni, Claudia
    Cordani, Nicoletta
    Cerrito, Maria Grazia
    Cazzaniga, Marina Elena
    LIFE-BASEL, 2022, 12 (03):
  • [22] Discovery of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2-breast cancer
    Majeski, Hannah
    Okano, Akinori
    Chahal, Kirti
    Pasis, Angela
    Carlson, Casey
    Shakya, Arvind
    Liu, Qiao
    Huang, Shenlin
    Chourasia, Aparajita Hoskote
    Fung, Leah
    CANCER RESEARCH, 2024, 84 (06)
  • [23] Real-world experience with CDK4/6 inhibitors for HR+/HER2-metastatic breast cancer (MBC)
    Abdallah, H. M. A.
    Owoseni, Y. I.
    Sultan, A.
    Ahmed, S.
    Wood, J.
    Varadhan, B.
    Ayodele, O.
    ANNALS OF ONCOLOGY, 2023, 34 : S369 - S370
  • [24] Impact of metastases directed radiation therapy on CDK4/6 inhibitors dose reduction and treatment discontinuation for metastatic HR+/HER2-breast cancer (MBC).
    Meattini, Icro
    Scoccimarro, Erika
    Saieva, Calogero
    Desideri, Isacco
    Visani, Luca
    Dominici, Luca
    Cerbai, Cecilia
    Aquilano, Michele
    Ciccone, Lucia Pia
    Palmieri, Valeria Emma
    Scotti, Vieri
    Nori, Jacopo
    Bernini, Marco
    Orzalesi, Lorenzo
    Sanchez, Luis
    Dieci, Maria Vittoria
    Bianchi, Simonetta
    Livi, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a real-world study in Italy
    Perrone, Valentina
    Dovizio, Melania
    Leogrande, Melania
    Tamma, Antonella
    Giovannitti, Massimo
    Buzzoni, Carlotta
    Esposti, Luca Degli
    BREAST CANCER MANAGEMENT, 2023, 12 (02)
  • [26] Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2-Early Breast Cancer
    Klocker, Eva Valentina
    Egle, Daniel
    Bartsch, Rupert
    Rinnerthaler, Gabriel
    Gnant, Michael
    DRUGS, 2025, 85 (02) : 149 - 169
  • [27] COST-EFFECTIVENESS OF CDK 4/6 INHIBITORS IN THE TREATMENT OF HR+/HER2-BREAST CANCER: A SYSTEMATIC REVIEW
    Bhatt, A.
    Nwosu, J.
    Zhong, L.
    VALUE IN HEALTH, 2023, 26 (06) : S69 - S69
  • [28] Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2-metastatic breast cancer: A machine learning approach
    Moiso, Enrico
    Ferraro, Emanuela
    Cabel, Luc
    Safonov, Anton
    Ahmed, Mehnaj
    An, Julia Ah-Reum
    Jhaveri, Komal L.
    Norton, Larry
    Robson, Mark E.
    Modi, Shanu
    Chandarlapaty, Sarat
    Razavi, Pedram
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Identifying genetic factors of response and resistance to CDK4/6 inhibitors in metastatic HR+/HER2-breast cancer using real-world data.
    Agrawal, Smita
    Singh, Neeraj
    Narayanan, Babu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Characterization of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2-breast cancer and glioblastoma multiforme
    Majeski, Hannah
    Chahal, Kirti
    Pasis, Angela
    Carlson, Casey
    Liu, Qiao
    Shakya, Arvind
    Okano, Akinori
    Huang, Shenlin
    Chourasia, Aparajita Hoskote
    Fung, Leah M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345